Blog
    Regulatory UpdateFor PhysiciansJune 8, 2026

    FDA peptide compounding status and safety signals

    Review FDA Category 2 classifications for BPC-157 and CJC-1295, plus emerging FAERS safety signals for GLP-1 RAs including NAION and pulmonary aspiration.

    Clinical Question

    What are the current FDA regulatory statuses for common therapeutic peptides, and what safety signals have emerged from clinical trials and postmarketing surveillance?

    Evidence Snapshot

    • Regulatory Classifications: Multiple peptides (BPC-157, TB-500, CJC-1295, Selank, Semax, Ipamorelin, GHK-Cu) are currently listed under FDA Category 2, indicating significant safety risks or lack of safety data.
    • FDA Warning Letters: Tailor Made Compounding (2020) and Predator Nutrition (2020) have received formal warnings regarding peptide distribution.
    • FAERS Safety Data: 187,757 GLP-1 RA adverse event (AE) reports through 2023, with emerging signals for NAION and pulmonary aspiration.
    • Clinical Efficacy (GLP-1/GIP/GCG): Weight loss ranging from 14.9% (Semaglutide) to 24.2% (Retatrutide) in Phase II/III trials.
    • Thymosin Alpha-1 Status: FDA-approved in 35+ countries (Zadaxin) but not in the U.S.; recently failed to reduce mortality in Phase III sepsis trials (NCT02867267).

    What the Research Shows

    FDA regulatory data as of March 2026 reveal a significant shift in the compounding landscape. Numerous peptides previously used in clinical settings are now classified as Category 2 substances. For example, BPC-157 is designated as a significant safety risk and is ineligible for routine compounding due to immunogenicity concerns and a lack of safety data. Similarly, TB-500 (Thymosin Beta-4) is cited for immunogenicity risk and a total lack of human exposure data.

    Several peptides, including AOD-9604, CJC-1295, Ipamorelin, and Selank, saw their nominations withdrawn or were removed from 503A compounding eligibility in September 2024. For CJC-1295, the FDA specifically cited safety issues such as increased heart rate. Thymosin Alpha-1, while approved as Zadaxin in over 35 countries, remains non-FDA approved in the U.S. and is currently listed as a substance of concern under interim policy following its removal from 503A eligibility in late 2024.

    In the realm of FDA-approved GLP-1 receptor agonists, clinical trials demonstrate robust efficacy but accompany a growing profile of adverse events. Semaglutide (STEP 1) achieved 14.9% weight loss, while Tirzepatide (SURMOUNT-1) reached 22.5%. In the SURMOUNT-5 trial, Tirzepatide demonstrated superiority to Semaglutide. Retatrutide, a triple agonist (Phase II), showed 24.2% weight loss at 12mg. However, FAERS data highlight significant risks, including 96 cases of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) through December 2024 and emerging signals for pulmonary aspiration, the latter of which was added to the Ozempic label in 2025.

    Mechanism

    Mechanistic data for these agents vary by class:

    • GLP-1 RAs (Semaglutide): Mechanism involves delayed gastric emptying, which contributes to weight loss but may also increase the risk of pulmonary aspiration during anesthesia and impact oral medication absorption.
    • Growth Hormone Secretagogues (CJC-1295): Associated with systemic effects including increased heart rate.
    • Copper Peptides (GHK-Cu) and GHRPs (GHRP-2): Associated with risks of immunogenicity.
    • Gastroprotective Peptides (BPC-157): Mechanism remains uncharacterized in U.S. regulatory reviews, which cite a lack of human safety data and immunogenicity concerns.

    Limitations of the Evidence

    There is a critical lack of human exposure data for several peptides including TB-500. For BPC-157, the FDA notes a significant absence of safety data. While FAERS data provide signals for Semaglutide, current data on suicidal ideation do not support a higher risk compared to background populations despite ongoing FDA monitoring. The clinical evidence for Thymosin Alpha-1 in sepsis was notably negative, failing to show a mortality reduction in Phase III trials (PMID: 39814420). Additionally, many substances including Selank and Semax are approved in international jurisdictions (Russia) but lack supporting data for FDA approval.

    Clinical Takeaway

    The regulatory status of peptides like BPC-157 and CJC-1295 has transitioned to Category 2, reflecting FDA concerns over immunogenicity and lack of safety profiles. While FDA-approved GLP-1 RAs show high efficacy for obesity and cardiovascular risk reduction, clinicians should monitor for emerging signals including NAION, pancreatitis, and intestinal obstruction. Compounding availability remains restricted for many of these agents as of March 2026.

    Sources

    • FDA Regulatory Status Records (BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, GHRP-2).
    • FAERS Safety Signal Database (Semaglutide reports 2023-2025).
    • Clinical Trial Records: NCT03548935 (STEP 1), NCT03574597 (SELECT), NCT04184622 (SURMOUNT-1), NCT05024032 (SURMOUNT-5), NCT04881706 (Retatrutide Phase II), NCT00451282 (Tesamorelin Phase III), NCT02867267 (Thymosin Alpha-1 Phase III).

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Referenced Peptides

    bpc 157semaglutidetirzepatidethymosin alpha 1cjc 1295

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.